CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
The abstracts describe early safety and efficacy data from the Phase 1b portion of Phase 1b/2 clinical trials evaluating NantCell's high-affinity natural killer (haNK) cell therapy in combination with anti-cancer agents, including aldoxorubicin, in patients with third-line or greater triple negative breast cancer (TNBC), fourth-line or greater head and neck squamous cell carcinoma (HNSCC) or recurrent metastatic pancreatic cancer.
These preliminary efficacy results are encouraging and the overall survival of 9.5 months currently exceeds all standards of care for patients at this advanced stage of disease.
http://www.cytrx.com/news-events/
NantCell und NantKwest gehören zu NantWorld
NantCell hat sich von CytRx Aldoxorubicin geschnappt.
NantKwest besitzt die haNK Technologioe.
Was ich an Studienergebnissen gelesen habe überzeugt mich kolossal!!